Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-wxhwt Total loading time: 0 Render date: 2024-07-12T21:10:03.752Z Has data issue: false hasContentIssue false

50 - Droxidopa

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Northera

Generic?

• No

Class

• Catecholamine analog

Commonly Prescribed for

(FDA approved in bold)

Treatment of symptomatic neurogenic orthostatic hypotension (orthostatic dizziness, lightheadedness, syncope) in adult patients caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, pure autonomic failure, familial amyloid polyneuropathy), dopamine β-hydroxylase deficiency, and non-diabetic autonomic neuropathy

• Freezing of gait in PD

• Postural tachycardia syndrome (POTS)

• Prevention of orthostasis in hemodialysis patients

• Fibromyalgia

• Attention deficit hyperactivity disorder

• Chronic fatigue

How the Drug Works

• It is a synthetic catecholamino acid analog that is directly metabolized by dopa-decarboxylase to increase the concentrations of norepinephrine and epinephrine throughout the body. It also crosses the BBB and exerts its pharmacological effects within the CNS. Peripherally, it increases blood pressure by inducing peripheral arterial and venous vasoconstriction. It induces small and transient rises in plasma norepinephrine

• The contribution of other actions of droxidopa to its pharmacological effect is not well understood

How Long Until It Works

• Few days

If It Works

• May continue for a longer time, although no available study on treatment more than 2 weeks so far

If It Doesn't Work

• Correct any treatable underlying disorders

• Volume expansion: high-salt diet, increased fluid intake, fluorohydrocortisone

• Vasoconstriction: desmopressin (vasopressin analog), midodrine (α1 agonist)

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Orthostasis: volume expansion and vasoconstriction

• POTS: volume expansion and vasoconstriction, exercise, cognitive behavioral therapy, propranolol, SNRIs, pyrostigmine

• Fibromyalgia: TCAs, SNRI, aerobic exercise, cognitive behavioral therapy

Tests

• None

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Elevated norepinephrine concentration

Notable AEs

• Headache, dizziness, nausea , supine hypertension, fatigue

Life-Threatening or Dangerous AEs

• Allergic reaction

• Neuroleptic malignant syndrome mimics (hyperpyrexia and confusion)

• May exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure

Weight Gain

• Unusual

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 186 - 188
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Droxidopa
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.051
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Droxidopa
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.051
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Droxidopa
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.051
Available formats
×